Adaptive Biotechnologies (ADPT) Common Equity (2018 - 2026)

Adaptive Biotechnologies has disclosed Common Equity across 9 years of filings, most recently posting $150.7 million for Q2 2026.

• In Q2 2026, Common Equity fell 16.08% year-over-year to $150.7 million; the TTM figure through Jun 2026 stood at $150.7 million (down 16.08% YoY), while the FY2025 annual figure was $225.0 million, up 11.12% from the prior year.
• Common Equity came in at $150.7 million for Q2 2026 at Adaptive Biotechnologies, down from $224.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $553.3 million in Q1 2022 to a low of $150.7 million in Q2 2026.
• Average Common Equity over 5 years is $312.8 million, with a median of $258.1 million recorded in 2024.
• Year-over-year, Common Equity sank 39.03% in 2024 and increased 17.88% in 2026.
• Over 5 years, Common Equity stood at $464.1 million in 2022, then plunged by 33.57% to $308.3 million in 2023, then tumbled by 34.32% to $202.5 million in 2024, then rose by 11.12% to $225.0 million in 2025, then slumped by 33.04% to $150.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $150.7 million in Q2 2026, $224.2 million in Q1 2026, and $225.0 million in Q4 2025.